Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood marker may reveal how well diabetes treatments are working

NCT ID NCT07734558

Knowledge-focused Sponsor: GÜLDEN ANATACA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This study looks at whether levels of a protein called Neuregulin-4 (NRG4) in the blood are linked to obesity, insulin resistance, and different diabetes treatments in people with type 2 diabetes. Researchers will compare NRG4 levels across groups including obese and non-obese patients on various medications, newly diagnosed patients, and healthy controls. The goal is to see if NRG4 could serve as a simple biomarker for metabolic health and treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If NRG4 levels reliably reflect metabolic status, it could become a simple blood test to help guide diabetes treatment.
What could go wrong
This is an observational study, not a treatment trial. It can only show associations, not cause and effect. The findings may not lead to a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of obese and non-obese adult participants aged 18-65 years who are admitted to the outpatient clinic. The study will include newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients, patients with at least 6 months of Type 2 DM diagnosis receiving different antidiabetic treatment combinations, and healthy control participants without diabetes mellitus.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 years * Newly diagnosed treatment-naïve T2DM * T2DM treated for at least 6 months * BMI \>30 kg/m² * BMI \<25 kg/m² * No pregnancy * No breastfeeding * No active infection * No inflammatory disease * Written informed consent Exclusion Criteria: * Age \<18 years * Pregnancy * Breastfeeding * Active infection * Rheumatologic disease * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Obesity type 2 diabetes mellitus Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kanuni Sultan Süleyman Training and Research Hospital

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.